Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
International journal of hematology, vol.117, pp.3-15, 2023 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 117
- Publication Date: 2023
- Doi Number: 10.1007/s12185-022-03446-1
- Journal Name: International journal of hematology
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
- Page Numbers: pp.3-15
- Istanbul University-Cerrahpasa Affiliated: Yes
Abstract
Patients diagnosed with chronic myeloid leukemia (CML) in chronic phase can now have a life expectancy comparable to that of the general population thanks to the use of tyrosine kinase inhibitor (TKI) therapies. Although most patients with CML require lifelong TKI therapy, it is possible for some patients to achieve treatment-free remission. These spectacular results have been made possible by the development of superior treatment modalities as well as clinicians' efforts in strictly adhering to clinical guidelines such as the National Comprehensive Cancer Network (NCCN) and European Leukemia Network (ELN). CML treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence. In this review, we provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines.